Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction

European Heart Journal, Supplement

Volumn 3, Issue A, 2001, Pages

  Antman, E M ^a   De Lemos, J A ^a   Braunwald, E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Abciximab; GP IIb IIIa receptor; Microvascular; Perfusion; ST segment resolution; TIMI 14

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; EPICARDIUM; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; ST SEGMENT; SURVIVAL; TREATMENT OUTCOME;

EID: 0034936471     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90019-7     Document Type: Conference Paper

References (25)

1. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
2. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
3. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
4. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis
5. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction
6. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment
7. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction
8. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
9. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
10. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody
11. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
12. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial
13. Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14
14. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
15. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
16. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction: Their relation to myocardial viability
17. Reperfusion revisited: Beyond TIMI 3 flow
18. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction
19. ST resolution at 90 and 180 minutes in patients with acute myocardial infarction treated with lanoteplase or alteplase: Results of the InTIME-2 ECG ST resolution substudy
20. Very early risk stratification after thrombolytic therapy using a bedside myoglobin assay and the 12-lead ECG
21. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy
22. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens
23. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial
24. Abciximab improves microvascular function after rescue PCI: A TIMI 14 substudy
25. A new angiographic method to assess myocardial perfusion and its relationship to mortality following thrombolytic administration: The TIMI Myocardial Perfusion Grade